Zika Virus Vaccines
The live-attenuated vaccine is developed for the disease caused by Zika Virus. The monovalent version of the vaccine is designed against Zika virus infection. Zika Virus belongs to the Genus Flavivirus, which is transmitted by the Aedes mosquitos. The understanding of flavivirus particle structure, the definition of E dimers as the key antigenic target, and a deep understanding of neutralization mechanisms help to develop the vaccine.
Related Conference of Zika Virus Vaccines
April 22-23, 2025
8th International Conference on Vaccines, Immunology and Clinical Trials
Paris, France
Zika Virus Vaccines Conference Speakers
Recommended Sessions
- Allergy & Asthma Vaccines
- Antibodies Research
- Chicken Pox Vaccines
- Clinical Immunology & Immunopathology
- Flu Vaccines
- HIV Vaccines
- HPV Vaccines
- Immune System Disorders
- Immunization Challenges
- Immunology
- Infectious and Non-infectious diseases Vaccines
- Onco-Immunology
- Paediatric Vaccines
- Pediatric Immunology
- Plant Vaccines & Veterinary Vaccines
- Recombinant Vaccines
- Stem Cell Immunology
- Therapeutic Cancer Vaccines
- Transplant Immunology
- Travel & Edible Vaccinations
- Vaccine Types
- Vaccine-Induced Immunity
- Vaccines
- Vaccines and Immunology Advancements
- Vaccines Efficacy and Safety
- Zika Virus Vaccines
Related Journals
Are you interested in
- Advancements in Vaccine Adjuvants - Vaccines R&D 2025 (France)
- Advances in Vaccine Safety Monitoring - Vaccines R&D 2025 (France)
- Antimicrobial Resistance (AMR) - VACCINES WORLD 2025 (Italy)
- Bioprocessing and Manufacturing - VACCINES WORLD 2025 (Italy)
- Biosecurity and Bioterrorism Preparedness - GLOBAL VACCINE 2025 (Indonesia)
- Cancer Vaccines and Immunotherapy - VACCINES WORLD 2025 (Italy)
- Cancer Vaccines and Immunotherapy - GLOBAL VACCINE 2025 (Indonesia)
- Cancer Vaccines and Immunotherapy - Euro Vaccines 2025 (France)
- Childhood Vaccines and Maternal Vaccines - Euro Vaccines 2025 (France)
- Clinical Trials - VACCINES WORLD 2025 (Italy)
- Clinical Trials and Regulatory Affairs - GLOBAL VACCINE 2025 (Indonesia)
- Clinical Trials and Vaccine Research - Vaccines R&D 2025 (France)
- Community Engagement and Public Health Campaigns - Vaccines R&D 2025 (France)
- Conjugate Vaccine - VACCINES WORLD 2025 (Italy)
- Conjugate Vaccine - GLOBAL VACCINE 2025 (Indonesia)
- Coronavirus (COVID-19) & Pandemic Vaccines - VACCINES WORLD 2025 (Italy)
- DNA Vaccines - Euro Vaccines 2025 (France)
- DNA-RNA Vaccines - VACCINES WORLD 2025 (Italy)
- Emerging and Re-Emerging Diseases - VACCINES WORLD 2025 (Italy)
- Emerging Technologies in Diagnostics - GLOBAL VACCINE 2025 (Indonesia)
- Epidemiology and Public Health - GLOBAL VACCINE 2025 (Indonesia)
- Ethics and Public Policy in Vaccination - Vaccines R&D 2025 (France)
- Fungal/Bacterial/Viral/Parasitic/STD Vaccines - VACCINES WORLD 2025 (Italy)
- Global Vaccine Distribution Challenges - Vaccines R&D 2025 (France)
- Hepatitis Vaccines - Euro Vaccines 2025 (France)
- HIV Vaccines - VACCINES WORLD 2025 (Italy)
- HIV Vaccines - GLOBAL VACCINE 2025 (Indonesia)
- HIV/AIDS Vaccines - Euro Vaccines 2025 (France)
- Human Preventive & Therapeutic Vaccines - Euro Vaccines 2025 (France)
- Human Vaccines - Infectious & Non Infectious Diseases - Euro Vaccines 2025 (France)
- Immune Profiling - VACCINES WORLD 2025 (Italy)
- Immunization Programs and Strategies - GLOBAL VACCINE 2025 (Indonesia)
- Immunology Advances and Vaccine Efficacy - Vaccines R&D 2025 (France)
- Immunology/Animal Models - Euro Vaccines 2025 (France)
- Impact of Climate Change on Infectious Disease and Vaccination - Vaccines R&D 2025 (France)
- Infectious and Non-Infectious Diseases - VACCINES WORLD 2025 (Italy)
- Influenza and Respiratory Vaccines - VACCINES WORLD 2025 (Italy)
- Innovations in Vaccine Formulation and Delivery - Vaccines R&D 2025 (France)
- Innovative Vaccine Development - GLOBAL VACCINE 2025 (Indonesia)
- Innovative Vaccine Technologies - Vaccines R&D 2025 (France)
- Integration of Digital Health in Immunization - Vaccines R&D 2025 (France)
- Mucosal Vaccines - Euro Vaccines 2025 (France)
- Nanotechnology in vaccines - GLOBAL VACCINE 2025 (Indonesia)
- Next-Generation Vaccine Delivery Technologies - Euro Vaccines 2025 (France)
- Next-Generation Vaccine Delivery Technologies - GLOBAL VACCINE 2025 (Indonesia)
- Pandemic Preparedness and Response - GLOBAL VACCINE 2025 (Indonesia)
- Personalized Immunization Strategies - Vaccines R&D 2025 (France)
- Rapid Vaccine Development and Deployment - Vaccines R&D 2025 (France)
- Technological Innovations in Vaccinology - GLOBAL VACCINE 2025 (Indonesia)
- Thermo Stabilized Vaccines - VACCINES WORLD 2025 (Italy)
- Thermo-stabilized vaccines - GLOBAL VACCINE 2025 (Indonesia)
- Vaccination in Special Populations - Vaccines R&D 2025 (France)
- Vaccine Access and Equity - GLOBAL VACCINE 2025 (Indonesia)
- Vaccine Adjuvants - Euro Vaccines 2025 (France)
- Vaccine Adjuvants - VACCINES WORLD 2025 (Italy)
- Vaccine Adjuvants - GLOBAL VACCINE 2025 (Indonesia)
- Vaccine Innovation for Emerging Diseases - Vaccines R&D 2025 (France)
- Vaccine Production, Supply & Logistics - VACCINES WORLD 2025 (Italy)
- Vaccine Research & Development - Euro Vaccines 2025 (France)
- Vaccine Research and Development - GLOBAL VACCINE 2025 (Indonesia)
- Vaccine Research and Development - VACCINES WORLD 2025 (Italy)
- Vaccine Safety, Efficacy & Regulatory Affairs - VACCINES WORLD 2025 (Italy)
- Vaccines against Viral and Bacterial Diseases - Euro Vaccines 2025 (France)
- Vaccines and Emerging Diseases - GLOBAL VACCINE 2025 (Indonesia)
- Vaccines Business Development - Euro Vaccines 2025 (France)
- Vaccines for Older Adults - Euro Vaccines 2025 (France)
- Vaccines for Respiratory Diseases - Euro Vaccines 2025 (France)
- Vaccines for Vector-borne Diseases - Euro Vaccines 2025 (France)
- Vaccines Safety & Efficacy - Euro Vaccines 2025 (France)
- Veterinary Vaccine - VACCINES WORLD 2025 (Italy)
- Veterinary Vaccines - Euro Vaccines 2025 (France)
- Veterinary vaccines - GLOBAL VACCINE 2025 (Indonesia)